HIF1A and neoplasm: Over the last decade, there has been increasing evidence for the critical role that HIF-1 and Wnt/β-catenin signaling play in the tumor adaptation to anti-angiogenic therapy [3, 8], suggesting that to improve patient outcome, the anti-angiogenic agents might have to be combined with Wnt/β-catenin signaling targeting drugs or inhibitors of tumor hypoxic adaptation.